

Tezspire® (tezepelumab-ekko) (Subcutaneous)

Document Number: M-P0650

Last Review Date: 07/01/2026

Date of Origin: 02/01/2022

Dates Reviewed: 02/2022, 07/2022, 10/2022, 03/2023, 10/2023, 10/2024, 01/2025, 03/2026, 07/2026

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 12 months (365 days).
- Renewal: Prior authorization validity may be renewed every 12 months (365 days) thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 210 billable units (210 mg) every 4 weeks

III. Initial Approval Criteria

For Medicaid Members Only

Patient must try and have an inadequate response, contraindication, or intolerance to at least a three (3) month trial of TWO of the following: mepolizumab (Nucala®), dupilumab (Dupixent®), omalizumab (Xolair®)

Target Agent(s) will be approved when ALL of the following are met:

1. ONE of the following:

- A. The requested agent is eligible for continuation of therapy AND ONE of the following:

Agents Eligible for Continuation of Therapy

All target agents are eligible for continuation of therapy

- The member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days; **OR**
- The prescriber states the member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed; **OR**

- B. BOTH of the following:

1. ONE of the following:

- A. The member has a diagnosis of severe asthma AND ONE of the following:

- The member has a history of uncontrolled asthma while on asthma control therapy (e.g., inhaled corticosteroid [ICS]/long-

acting beta-2 agonist [LABA] combination therapy) as demonstrated by ONE of the following:

- A. Two or more severe asthma exacerbations (i.e., required treatment with a systemic corticosteroid [steroid burst]) within the past 12 months; **OR**
 - B. One or more serious asthma exacerbation(s) (i.e., required hospitalization, mechanical ventilation, or visit to the emergency room or urgent care) within the past 12 months; **OR**
 - C. Controlled asthma that worsens when the doses of inhaled and/or systemic corticosteroids are tapered; **OR**
 - D. Baseline (prior to therapy with the requested agent) Forced Expiratory Volume (FEV1) that is less than 80% of predicted; **OR**
2. The member's medication history (excluding sample use) indicates use of a biologic immunomodulator agent that is FDA labeled or supported in compendia for the treatment of asthma within the past 12 months; **OR**
- B. The member has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND ALL of the following:
- 1. ONE of the following:
 - A. The member is an adult AND has at least TWO of the following symptoms consistent with chronic rhinosinusitis (CRS):
 - 1. Nasal discharge (rhinorrhea or post-nasal drainage)
 - 2. Nasal obstruction or congestion
 - 3. Facial pressure or pain
 - 4. Loss or decreased sense of smell (hyposmia); **OR**
 - B. The member is a pediatric member AND has at least TWO of the following symptoms consistent with chronic rhinosinusitis (CRS):
 - 1. Nasal discharge (rhinorrhea or post-nasal drainage)
 - 2. Nasal obstruction or congestion
 - 3. Facial pressure or pain
 - 4. Cough; **AND**
 - 2. The member has had symptoms consistent with chronic rhinosinusitis (CRS) for at least 12 consecutive weeks; **AND**
 - 3. The member's diagnosis was confirmed by ONE of the following:

- A. Anterior rhinoscopy; **OR**
 - B. Nasal endoscopy; **OR**
 - C. Computed tomography (CT) of the sinuses; **AND**
 - 4. The member has ONE of the following:
 - A. Tried and had an inadequate response to ONE intranasal corticosteroid (e.g., fluticasone nasal spray, mometasone nasal spray, Sinuva) after at least a 4-week duration of therapy; **OR**
 - B. An intolerance or hypersensitivity to ONE intranasal corticosteroid (e.g., fluticasone nasal spray, mometasone nasal spray, Sinuva); **OR**
 - C. An FDA labeled contraindication to ALL intranasal corticosteroids; **OR**
 - C. The member has another FDA labeled indication for the requested agent and route of administration; **AND**
- 2. If the member has an FDA labeled indication, then ONE of the following:
 - A. The member's age is within FDA labeling for the requested indication for the requested agent; **OR**
 - B. There is support for using the requested agent for the member's age for the requested indication; **OR**
- C. The member has an indication that is supported in compendia for the requested agent and route of administration; **AND**
- 2. If the member has a diagnosis of severe asthma, then ALL of the following:
 - A. ONE of the following
 - 1. The member is NOT currently treated with a biologic immunomodulator agent that is FDA labeled or supported in compendia for the treatment of asthma (including the requested agent) AND is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months AND has been adherent for 90 days within the past 120 days; **OR**
 - 2. The member is currently treated with a biologic immunomodulator agent that is FDA labeled or supported in compendia for the treatment of asthma (including the requested agent) AND ONE of the following:
 - A. The member is currently treated with an inhaled corticosteroid for at least 3 months that is adequately dosed to control symptoms AND has been adherent for 90 days within the past 120 days; **OR**

- B. The member is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months AND has been adherent for 90 days within the past 120 days; **OR**
 - 3. The member has an intolerance or hypersensitivity to ONE inhaled corticosteroid; **OR**
 - 4. The member has an FDA labeled contraindication to ALL inhaled corticosteroids; **AND**
 - B. ONE of the following:
 - 1. The member is currently treated for at least 3 months AND has been adherent for 90 days within the past 120 days with ONE of the following:
 - A. A long-acting beta-2 agonist (LABA); **OR**
 - B. A long-acting muscarinic antagonist (LAMA); **OR**
 - C. A leukotriene receptor antagonist (LTRA); **OR**
 - D. Theophylline; **OR**
 - 2. The member has an intolerance or hypersensitivity to ONE long-acting beta-2 agonist (LABA), long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist (LTRA), or theophylline; **OR**
 - 3. The member has an FDA labeled contraindication to ALL long-acting beta-2 agonists (LABA) AND long-acting muscarinic antagonists (LAMA); **AND**
 - C. The member will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent; **AND**
3. If the member has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), then BOTH of the following:
- A. The member is currently treated with standard nasal polyp maintenance therapy (e.g., nasal saline irrigation, intranasal corticosteroids [e.g., fluticasone nasal spray, mometasone nasal spray, Sinuva]); **AND**
 - B. The member will continue standard nasal polyp maintenance therapy (e.g., nasal saline irrigation, intranasal corticosteroids [e.g., fluticasone nasal spray, mometasone nasal spray, Sinuva]) in combination with the requested agent; **AND**
4. The prescriber is a specialist in the area of the member's diagnosis (e.g., asthma: allergist, immunologist, pulmonologist; CRSwNP: otolaryngologist, allergist, immunologist, pulmonologist), or the prescriber has consulted with a specialist in the area of the member's diagnosis; **AND**
5. ONE of the following (Please refer to "Agents NOT to be used Concomitantly" table):
- A. The member will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors); **OR**

- B. The member will be using the requested agent in combination with another immunomodulatory agent AND BOTH of the following:
 - 1. The prescribing information for the requested agent does NOT limit the use with another immunomodulatory agent; **AND**
 - 2. There is support for the use of combination therapy (submitted copy of clinical trials, phase III studies, or guidelines required); **AND**
- 6. The member does NOT have any FDA labeled contraindications to the requested agent

Compendia Allowed: AHFS, DrugDex 1 or 2a level of evidence, or NCCN 1 or 2a recommended use

IV. Renewal Criteria

Target Agent(s) will be approved when ALL of the following are met:

- 1. The member has been previously approved for the requested agent through the plan's Prior Authorization process (Note: members not previously approved for the requested agent will require initial evaluation review); **AND**
- 2. The member has had clinical benefit with the requested agent; **AND**
- 3. If the member has a diagnosis of severe asthma, then the member is currently treated within the past 90 days and is compliant with asthma control therapy (e.g., inhaled corticosteroids [ICS], ICS/long-acting beta-2 agonist [ICS/LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], theophylline); **AND**
- 4. If the member has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), then the member will continue standard nasal polyp maintenance therapy (e.g., nasal saline irrigation, intranasal corticosteroids [e.g., fluticasone nasal spray, mometasone nasal spray, Sinuva]) in combination with the requested agent; **AND**
- 5. The prescriber is a specialist in the area of the member's diagnosis (e.g., asthma: allergist, immunologist, pulmonologist; CRSwNP: otolaryngologist, allergist, immunologist, pulmonologist), or the prescriber has consulted with a specialist in the area of the member's diagnosis; **AND**
- 6. ONE of the following (Please refer to "Agents NOT to be used Concomitantly" table):
 - A. The member will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors); **OR**
 - B. The member will be using the requested agent in combination with another immunomodulatory agent AND BOTH of the following:
 - 1. The prescribing information for the requested agent does NOT limit the use with another immunomodulatory agent; **AND**

2. There is support for the use of combination therapy (submitted copy of clinical trials, phase III studies, or guidelines required); **AND**

7. The member does NOT have an FDA labeled contraindications to the requested agent

Contraindicated as Concomitant Therapy

Agents NOT to be used Concomitantly

Abrilada (adalimumab-afzb)
Actemra (tocilizumab)
Adalimumab
Adbry (tralokinumab-ldrm)
Amjevita (adalimumab-atto)
Anzupgo (delgocitinib)
Arcalyst (rilonacept)
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
Benlysta (belimumab)
Bimzelx (bimekizumab-bkzx)
Cibinqo (abrocitinib)
Cimzia (certolizumab)
Cinqair (reslizumab)
Cosentyx (secukinumab)
Cyltezo (adalimumab-adbm)
Dupixent (dupilumab)
Ebglyss (lebrikizumab-lbkz)
Enbrel (etanercept)
Entyvio (vedolizumab)
Exdensus (depemokimab-ulaa)
Fasenra (benralizumab)
Hadlima (adalimumab-bwwd)
Hulio (adalimumab-fkjp)
Humira (adalimumab)
Hyrimoz (adalimumab-adaz)
Icotyde (icotrokinra)
Idacio (adalimumab-aacf)
Ilaris (canakinumab)
Ilumya (tildrakizumab-asmn)

Contraindicated as Concomitant Therapy

Imuldosa (ustekinumab-srlf)
Inflectra (infliximab-dyyb)
Infliximab
Kevzara (sarilumab)
Kineret (anakinra)
Leqselvi (deuruxolitinib)
Litfulo (ritlecitinib)
Nemluvio (nemolizumab-ilto)
Nucala (mepolizumab)
Olumiant (baricitinib)
Omlyclo (omalizumab-igec)
Omvoh (mirikizumab-mrkz)
Opzelura (ruxolitinib)
Orencia (abatacept)
Otezla (apremilast)
Otezla XR (apremilast extended-release)
Otulfi (ustekinumab-aauz)
Pyzchiva (ustekinumab-ttwe)
Remicade (infliximab)
Renflexis (infliximab-abda)
Rhapsido (remibrutinib)
Riabni (rituximab-arrr)
Rinvoq (upadacitinib)
Rituxan (rituximab)
Rituxan Hycela (rituximab/hyaluronidase human)
Ruxience (rituximab-pvvr)
Saphnelo (anifrolumab-fnia)
Selarsdi (ustekinumab-aekn)
Siliq (brodalumab)
Simlandi (adalimumab-ryvk)
Simponi (golimumab)
Simponi ARIA (golimumab)
Skyrizi (risankizumab-rzaa)
Sotyktu (deucravacitinib)
Spevigo (spesolimab-sbzo) subcutaneous injection

Contraindicated as Concomitant Therapy

Starjemza (ustekinumab-hmny)
Stelara (ustekinumab)
Steqeyma (ustekinumab-stba)
Taltz (ixekizumab)
Tezspire (tezepelumab-ekko)
Tofacitinib
Tofidence (tocilizumab-bavi)
Tremfya (guselkumab)
Truxima (rituximab-abbs)
Tyenne (tocilizumab-aazg)
Tyruko (natalizumab-sztn)
Tysabri (natalizumab)
Ustekinumab
Velsipity (etrasimod)
Wezlana (ustekinumab-auub)
Xeljanz (tofacitinib)
Xeljanz XR (tofacitinib extended release)
Xolair (omalizumab)
Yesintek (ustekinumab-kfce)
Yuflyma (adalimumab-aaty)
Yusimry (adalimumab-aqvh)
Zeposia (ozanimod)
Zymfentra (infliximab-dyyb)

V. Dosage/Administration

Indication	Dose
All indications	Administer 210 mg subcutaneously once every 4 weeks.

VI. Billing Code/Availability Information

HCPCS Code:

- J2356 – Injection, tezepelumab-ekko, 1 mg; 1 billable unit = 1 mg

NDC(s):

- Tezspire 210 mg/1.91 mL single-dose prefilled pen: 55513-0123-xx
- Tezspire 210 mg/1.91 mL single-dose prefilled syringe: 55513-0112-xx

- Tezspire 210 mg/1.91 mL single-dose vial: 55513-0100-xx

VII. References

1. Tezspire prescribing information. Amgen Inc. October 2025.
2. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. *European Respiratory Journal*. 2022;60(3):2101585. doi:10.1183/13993003.01585-2021
3. Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention (2025 Update)*. 2025. <https://www.ginasthma.org>
4. Chung KF, Wenzel SE, Brożek J, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *The European Respiratory Journal*. 2014;43(2):343-373. doi:10.1183/09031936.00202013
5. Bourdin A, Brusselle G, Couillard S, et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. *The Journal of Allergy and Clinical Immunology in Practice*. 2024;12(4):809-823. doi:10.1016/j.jaip.2024.01.023
6. Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol*. 2023;151(2):386-398. doi:10.1016/j.jaci.2022.10.026
7. Payne SC, McKenna M, Buckley J, et al. Clinical Practice Guideline: Adult Sinusitis Update. *Otolaryngol Head Neck Surg*. 2025;173(S1):S1-S56. doi:10.1002/ohn.1344
8. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. *International Forum of Allergy & Rhinology*. 2021;11(3):213-739. doi:10.1002/alr.22741
9. Fokkens W, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology*. 2020;58(S29):1-464. doi:10.4193/rhin20.600
10. Fokkens WJ, Viskens A, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. *Rhinology*. 2023;61(3):194-202. doi:10.4193/rhin22.489

Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior

authorization to this drug/drug group, and a summary of the conclusions that Prime's assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	No: PA not a priority
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified
J45.50	Severe persistent asthma, uncomplicated

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC